This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction. Weighing the Evidence: Weight Management Insights for Treating Major Mental Illness

Leslie Citrome, MD, MPH

Published: September 14, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Second-generation antipsychotics (SGAs), or "atypical" antipsychotics, have become the dominant treat ment choice for patients with schizophrenia and have alsobeen used as monotherapy and in combination therapy with lithium and anticonvulsants in the treatment of bipolar disorder. The advantage of SGAs over the older "neuroleptics" has principally been in their lower propensity for extrapyramidal side effects, including tremor, rigidity, and akathisia. Also, evidence has shown that SGAs have a broad spectrum of therapeutic action regarding negative symptoms, including mood dysregulation, hostility, cognitive dysfunction, and comorbid alcohol and substance abuse.1‘ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: